CA2923166A1 - Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy - Google Patents

Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy Download PDF

Info

Publication number
CA2923166A1
CA2923166A1 CA2923166A CA2923166A CA2923166A1 CA 2923166 A1 CA2923166 A1 CA 2923166A1 CA 2923166 A CA2923166 A CA 2923166A CA 2923166 A CA2923166 A CA 2923166A CA 2923166 A1 CA2923166 A1 CA 2923166A1
Authority
CA
Canada
Prior art keywords
subject
breast cancer
biological sample
subtype
luminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2923166A
Other languages
English (en)
French (fr)
Inventor
Maggie Chon U. CHEANG
Torsten O. NEILSEN
Charles M. Perou
Matthew J. Ellis
Philip S. Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
University of North Carolina at Chapel Hill
Washington University in St Louis WUSTL
University of Utah Research Foundation Inc
Original Assignee
British Columbia Cancer Agency BCCA
University of North Carolina at Chapel Hill
Washington University in St Louis WUSTL
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, University of North Carolina at Chapel Hill, Washington University in St Louis WUSTL, University of Utah Research Foundation Inc filed Critical British Columbia Cancer Agency BCCA
Publication of CA2923166A1 publication Critical patent/CA2923166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2923166A 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy Abandoned CA2923166A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361875373P 2013-09-09 2013-09-09
US61/875,373 2013-09-09
US201461990948P 2014-05-09 2014-05-09
US61/990,948 2014-05-09
PCT/US2014/054760 WO2015035377A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Publications (1)

Publication Number Publication Date
CA2923166A1 true CA2923166A1 (en) 2015-03-12

Family

ID=51688397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923166A Abandoned CA2923166A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Country Status (7)

Country Link
US (1) US20150072021A1 (enExample)
EP (1) EP3044332A1 (enExample)
JP (1) JP2016537010A (enExample)
AU (1) AU2014317843A1 (enExample)
CA (1) CA2923166A1 (enExample)
IL (1) IL244421A0 (enExample)
WO (1) WO2015035377A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
SG11201704177SA (en) 2014-11-24 2017-06-29 Nanostring Technologies Inc Methods and apparatuses for gene purification and imaging
JP2018500895A (ja) * 2014-12-09 2018-01-18 キングス・カレッジ・ロンドン タキサン療法による乳癌治療
MX2018005867A (es) * 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN108456730B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用
US12352750B2 (en) 2019-04-04 2025-07-08 University Of Utah Research Foundation Multigene assay to assess risk of recurrence of cancer
KR102414754B1 (ko) * 2019-10-10 2022-06-30 주식회사 종근당 직장암 항암화학방사선 치료 반응 예측용 바이오마커
TW202129008A (zh) * 2019-11-05 2021-08-01 香港商行動基因（智財）有限公司 檢測異檸檬酸脫氫酶突變的套組及方法
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
KR20240081508A (ko) 2022-11-17 2024-06-10 인제대학교 산학협력단 Dna 메틸화 변화를 통한 방사선치료 반응성 예측용 바이오마커 조성물 및 이의 용도
CN116622885B (zh) * 2023-05-23 2025-01-10 福建省农业科学院果树研究所 一种用于不同桃花色鉴定的分子标记方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
CA2118806A1 (en) 1991-09-18 1993-04-01 William J. Dower Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
AU675054B2 (en) 1991-11-22 1997-01-23 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
WO2006010150A2 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
JP5700911B2 (ja) 2005-12-23 2015-04-15 ナノストリング テクノロジーズ，インコーポレーテッド 配向され、固定化された巨大分子を含む組成物とその製造法
EP1963531B1 (en) 2005-12-23 2011-09-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US7892740B2 (en) * 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
CA2687292C (en) 2007-04-10 2017-07-04 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
EP2195467B1 (en) * 2007-09-06 2016-12-14 bioTheranostics, Inc. Tumor grading and cancer prognosis in breast cancer
JP2010539890A (ja) * 2007-09-14 2010-12-24 ユニヴァーシティ オブ サウス フロリダ 放射線治療の応答を予測するための遺伝子シグネチャー
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
ES2614810T3 (es) 2008-08-14 2017-06-02 Nanostring Technologies, Inc Nanoindicadores estables
EP2785873A4 (en) * 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
IN2014MN02418A (enExample) * 2012-05-22 2015-08-14 Nanostring Technologies Inc

Also Published As

Publication number Publication date
AU2014317843A1 (en) 2016-03-24
IL244421A0 (en) 2016-04-21
US20150072021A1 (en) 2015-03-12
EP3044332A1 (en) 2016-07-20
WO2015035377A1 (en) 2015-03-12
JP2016537010A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
US20230272476A1 (en) Nano46 genes and methods to predict breast cancer outcome
CA2923166A1 (en) Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
US20140037620A1 (en) Methods of Treating Breast Cancer with Gemcitabine Therapy
US9181588B2 (en) Methods of treating breast cancer with taxane therapy
US9066963B2 (en) Methods of treating breast cancer with anthracycline therapy
US20160115551A1 (en) Methods to predict risk of recurrence in node-positive early breast cancer
US20160160293A1 (en) Breast cancer treatment with taxane therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190910

FZDE Discontinued

Effective date: 20190910